NCT02079740 2025-09-30
Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
Clinical Trials
4 trialsNCT01902173 2025-01-14
Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT02097225 2024-10-16
Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 1 Terminated
NCT05071183 2024-04-02
A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors
Turning Point Therapeutics, Inc.
Phase 1/2 Terminated